Enliven Therapeutics (ELVN) Current Assets (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Current Assets data on file, last reported at $463.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 57.36% year-over-year to $463.1 million; the trailing twelve-month figure through Mar 2026 stood at $463.1 million (up 57.36% YoY), and the FY2025 full-year result was $474.9 million, up 49.27% from the prior year.
• Current Assets retreated to $463.1 million in Q1 2026, from $474.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $495.6 million in Q2 2025 to a low of $59.1 million in Q3 2022.
• A 5-year average of $286.9 million and a median of $297.0 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 44.24% in 2022 and soared 354.46% in 2023, its largest moves.
• Tracing ELVN's Current Assets over 5 years: stood at $77.8 million in 2022, then surged by 242.3% to $266.2 million in 2023, then gained by 19.53% to $318.1 million in 2024, then jumped by 49.27% to $474.9 million in 2025, then decreased by 2.47% to $463.1 million in 2026.
• Business Quant data shows ELVN's Current Assets at $463.1 million in Q1 2026, $474.9 million in Q4 2025, and $482.7 million in Q3 2025.